Salarius Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
David Arthur
Algemeen directeur
US$355.7k
Totale compensatie
Percentage CEO-salaris | 92.8% |
Dienstverband CEO | 5.3yrs |
Eigendom CEO | 0.4% |
Management gemiddelde ambtstermijn | geen gegevens |
Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
Salarius pharmaceuticals announces 1-for-25 reverse stock split
Oct 14Salarius adds 12% after updates on clinical programs and financials
Sep 13Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers
Aug 22Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01
Aug 08Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement
Aug 02Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21
Jun 07Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
May 27Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain
Feb 09Salarius Pharmaceuticals receives second installment of $1.7M in payments
Jan 13Salarius Pharma raises $3.5M via warrant exercise
Dec 11Salarius Pharmaceuticals EPS in-line, beats on revenue
Nov 11Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$6m |
Mar 31 2024 | n/a | n/a | -US$9m |
Dec 31 2023 | US$356k | US$330k | -US$13m |
Sep 30 2023 | n/a | n/a | -US$18m |
Jun 30 2023 | n/a | n/a | -US$30m |
Mar 31 2023 | n/a | n/a | -US$31m |
Dec 31 2022 | US$941k | US$500k | -US$32m |
Sep 30 2022 | n/a | n/a | -US$29m |
Jun 30 2022 | n/a | n/a | -US$19m |
Mar 31 2022 | n/a | n/a | -US$17m |
Dec 31 2021 | US$677k | US$379k | -US$13m |
Sep 30 2021 | n/a | n/a | -US$11m |
Jun 30 2021 | n/a | n/a | -US$9m |
Mar 31 2021 | n/a | n/a | -US$8m |
Dec 31 2020 | US$1m | US$340k | -US$8m |
Sep 30 2020 | n/a | n/a | -US$7m |
Jun 30 2020 | n/a | n/a | -US$8m |
Mar 31 2020 | n/a | n/a | -US$7m |
Dec 31 2019 | US$518k | US$315k | -US$7m |
Sep 30 2019 | n/a | n/a | -US$6m |
Jun 30 2019 | n/a | n/a | -US$4m |
Mar 31 2019 | n/a | n/a | -US$3m |
Dec 31 2018 | US$275k | US$258k | -US$2m |
Compensatie versus markt: De totale vergoeding ($USD 355.70K ) David } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 651.15K ).
Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
David Arthur (61 yo)
5.3yrs
Tenure
US$355,700
Compensatie
Mr. David J. Arthur, M.B.A., has been President at Salarius Pharmaceuticals, Inc since July 19, 2019 and Chief Executive Officer & Director at Salarius Pharmaceuticals, Inc. since July 2019. Mr. Arthur ser...
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | 5.3yrs | US$355.70k | 0.43% $ 9.0k | |
Independent Director | 4.4yrs | US$53.76k | 0.026% $ 541.1 | |
Independent Director | 5.3yrs | US$45.26k | 0.012% $ 264.6 | |
Independent Director | 5.3yrs | US$67.26k | 0.029% $ 605.7 | |
Chairman of the Board | 5.3yrs | US$82.26k | 0.025% $ 523.3 | |
Independent Director | 5.3yrs | US$64.76k | 0.024% $ 499.8 |
5.3yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SLRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).